Cassava Sciences | PTIE - Gross Profit On Sales


Cassava Sciences reported $-3.96M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Eisai JPY 153.41B 15.44B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Geron USD 50.14M 3.44M Mar/2026
J&J USD 17.24B 642M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025